First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report
Molecular Therapy: Oncology
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all
First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all
“First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report.” Molecular Therapy: Oncology.
@article{article59021,
title = {First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all}
}